share_log

6-K: Novo Nordisk A/S – Reduction of the Share Capital

6-K: Novo Nordisk A/S – Reduction of the Share Capital

诺和诺德 | 6-K：诺和诺德 - 股本削减
美股sec公告 ·  04/25 06:05
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
Novo Nordisk A/S, a leading global healthcare company, has successfully completed the reduction of its B share capital as announced at its Annual General Meeting on March 21, 2024. The reduction involved the cancellation of 45,000,000 B shares, resulting in a decrease of the B share capital from DKK 343,512,800 to DKK 339,012,800. Following the reduction, the total share capital of Novo Nordisk stands at DKK 446,500,000, split into A and B shares. The company confirmed that this capital adjustment will not impact its ongoing share repurchase program. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people across 80 countries. The company's B shares are traded on Nasdaq Copenhagen, and its ADRs are listed on the New York Stock Exchange under the ticker NVO.
全球领先的医疗保健公司诺和诺德A/S已成功完成其在2024年3月21日的年度股东大会上宣布的B股本削减。削减涉及取消45,000,000股B股，导致B股本从343,512,800丹麦克朗减少至339,012,800丹麦克朗。减持后，诺和诺德的总股本为44.65万丹麦克朗，分为A股和B股。该公司证实，此次资本调整不会影响其正在进行的股票回购计划。诺和诺德的历史可以追溯到1923年，致力于抗击严重的慢性病，在80个国家拥有约63,400名员工。该公司的B股在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市，股票代码为NVO。
全球领先的医疗保健公司诺和诺德A/S已成功完成其在2024年3月21日的年度股东大会上宣布的B股本削减。削减涉及取消45,000,000股B股，导致B股本从343,512,800丹麦克朗减少至339,012,800丹麦克朗。减持后，诺和诺德的总股本为44.65万丹麦克朗，分为A股和B股。该公司证实，此次资本调整不会影响其正在进行的股票回购计划。诺和诺德的历史可以追溯到1923年，致力于抗击严重的慢性病，在80个国家拥有约63,400名员工。该公司的B股在哥本哈根纳斯达克上市，其ADR在纽约证券交易所上市，股票代码为NVO。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息